This article was automatically generated by Dow Jones using technology from Automated Insights.

The following companies are among those expected to report their latest financial results before the market opens.

Mastercard Inc.'s second-quarter EPS is forecast at $4.75. Adjusted EPS is forecast at $4.77.

Bristol Myers Squibb Co.'s second-quarter EPS is forecast at $1.35, compared with $1.08 in the prior-year period. Adjusted EPS is forecast at $1.60.

Altria Group Inc.'s second-quarter EPS is forecast at $1.50, compared with $1.41 in the prior-year period.

Southern Co.'s second-quarter EPS is forecast at $1.01, compared with 79 cents in the prior-year period.

KKR & Co. Inc.'s second-quarter EPS is forecast at $1.42, compared with 50 cents in the prior-year period. Adjusted EPS is forecast at $1.43.

Valero Energy Corp.'s second-quarter EPS is forecast at $10.06, compared with $2.28 in the prior-year period. Adjusted EPS is forecast at $10.13.

Quanta Services Inc.'s second-quarter EPS is forecast at $2.26, compared with $1.52 in the prior-year period. Adjusted EPS is forecast at $3.31.

Intercontinental Exchange Inc.'s second-quarter EPS is forecast at $1.60, compared with $1.48 in the prior-year period. Adjusted EPS is forecast at $1.84.

Enterprise Products Partners L.P.'s second-quarter EPS is forecast at 75 cents, compared with 66 cents in the prior-year period.

Cigna Group's second-quarter EPS is forecast at $6.41, compared with $5.71 in the prior-year period. Adjusted EPS is forecast at $7.60.

American Electric Power Co. Inc.'s second-quarter EPS is forecast at $1.49, compared with $2.29 in the prior-year period. Adjusted EPS is forecast at $1.48.

Air Products & Chemicals Inc.'s third-quarter EPS is forecast at $3.36, compared with $3.20 in the prior-year period. Adjusted EPS is forecast at $3.34.

Xcel Energy Inc.'s second-quarter EPS is forecast at 79 cents, compared with 75 cents in the prior-year period.

Exelon Corp.'s second-quarter EPS is forecast at 43 cents, compared with 39 cents in the prior-year period. Adjusted EPS is forecast at 44 cents.

Alnylam Pharmaceuticals Inc.'s second-quarter EPS is forecast at $1.63, compared with a loss of 51 cents in the prior-year period.

Generated from Dow Jones Calendar Live with data from Dow Jones and Factset.